Back to Press Releases

The subscription period in Annexin Pharmaceutical’s rights issue commences today


Today is the first day of the subscription period in Annexin Pharmaceuticals AB’s (publ) ("Annexin" or the “Company") rights issue of units consisting of shares and warrants of series TO3 ("Units") which was resolved upon by the Extraordinary General Meeting on October 8, 2021 (the "Rights Issue") and in which the general public also has the opportunity to apply for subscription of Units.


Annexin carries out the Rights Issue to finance forthcoming clinical studies as well as additional costs in connection with research and development of the ANXV program. Upon full subscription in the Rights Issue, Annexin will initially receive approximately SEK 73.5 million before issue costs. The rights issue is 100 percent secured through subscription undertakings and guarantee commitments.


Upon full exercise of the warrants of series TO3, the Company will receive an additional approximately SEK 18-29 million (depending on the final exercise price for the new shares that may be subscribed for through the exercise of warrants). The warrants will be admitted to trading on the Nasdaq First North Growth Market (”First North”).


For complete information on the Rights Issue, please see the prospectus, which has been prepared and published by the Board of Directors in connection with the Rights Issue.


The rights issue

The Rights Issue comprises a maximum of 58,817,169 Units containing shares and warrants. One (1) existing share in the Company entitles to three (3) unit rights and four (4) unit rights entitle to subscribe for one (1) Unit. One (1) Unit consists of one (1) share and one (1) warrant of series TO3. The subscription price is SEK 1.25 per Unit, corresponding to SEK 1.25 per share.


The warrants of series TO3 will be issued free of charge and can be exercised for subscription of new shares during the period 14-28 April 2022. Four (4) warrants of series TO3 are required for subscription of one (1) new share at a subscription price corresponding to 70 percent of the volume-weighted average price paid for the Company's share on First North during a period of ten (10) trading days immediately preceding April 12, 2022, however, a minimum of SEK 1.25 and a maximum of SEK 2 per share.


Preliminary timeline

  • October 20 – 29, 2021 – Trading in unit rights
  • October 20, 2021 – November 3, 2021 – Subscription period
  • October 20, 2021 – Until the Rights Issue is registered with the Swedish Companies Registration Office -Trading in paid subscribed units (BTU)
  • November 8, 2021 – Announcement of outcome of the Rights Issue
  • April 14 – 28, 2022 – Exercise period for warrants of series TO3
  • Week 18, 2022 – Estimated announcement of outcome of exercise of warrants of series TO3

Investor presentations

Annexin will present at Redeye Investor Forum on October 28, 2021. Additional investor presentations may be arranged during the subscription period. Invitation to these will be presented on Annexins and Redeye AB's respective websites.



The prospectus, containing complete terms and conditions, is available on the Company's, Hagberg Aneborn Fondkommission AB's and Redeye AB's respective websites (,, The prospectus will also be available on the Swedish Financial Supervisory Authority's website ( Subscription forms will be sent to the shareholders or the representatives of shareholders who are registered on the record date 15 October 2021 in the share register kept by Euroclear and will also be made available on the Company's and Redeye AB's respective websites. Furthermore, subscription forms can also be obtained by contacting the Hagberg Aneborn on telephone number 08-408 933 50.


Redeye AB acts as financial adviser, Cirio Advokatbyrå AB acts as legal adviser and Hagberg Aneborn Fondkommission AB acts as the issuing agent in the Rights Issue.


For further information, please contact:

Anders Haegerstrand, CEO, tel 070 – 575 50 37


The information was provided, under the above contact person's auspices, for publication on 20 October 2021 at 08.30 CET.


About Annexin AB

Annexin Pharmaceuticals AB (publ) is a world-leading biotechnology company in the Annexin A5 field, for treatment of various cardiovascular diseases, which are currently the most common cause of death. The Company’s biological drug candidate ANXV – a human recombinant protein, Annexin A5 – is intended primarily for the acute treatment of patients with vascular damages and inflammation. The Company also has a comprehensive patent portfolio for the treatment of diseases caused by vascular damage and inflammation. Annexin Pharmaceuticals has established and optimized a cell line for large-scale production of Annexin A5. The Company is based i Stockholm and is listed on Nasdaq First North Growth Market, short name ANNX. Redeye is the Company’s Certified Adviser. Tel. +46 (0) 8 121 576 90, email



The information in this press release does not constitute an offer to acquire, subscribe for or otherwise trade with shares, warrants or other securities in Annexin. No action has been taken, nor will any actions be taken, to permit an offer to the public in any other jurisdiction than Sweden. An invitation to eligible persons to subscribe for Units or other securities in Annexin will only be made through the prospectus which Annexin published on October 19, 2021.


The information in this press release may not be published or distributed, directly or indirectly, within or into the United States of America (including its territories and possessions, any state of the United States and the District of Columbia, the “USA”), Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa or South Korea or any jurisdiction where doing so might be unlawful, subject to legal restrictions or require other actions than the ones prescribed under Swedish law. Actions in violation of these instructions may constitute a breach of applicable securities law. This press release does not constitute an offer of invitation to acquire or subscribe for shares or other securities in the USA. No shares, warrants, unit rights, BTU or Units or other securities issued by the Company (the “Securities”) have been, nor will they be, registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) or the securities laws in any other state or jurisdiction in the USA and no Securities may be offered, subscribed, used, pledged, sold, retailed, delivered or transferred, directly or indirectly, in or into the USA other than pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the USA. The Securities have not been and will not be approved or registered by the Securities and Exchange Commission, any state securities authority or other authority in the USA. No such authority has assessed or made any statements about the Rights Issue or the accuracy or reliability of the prospectus. To assert the contrary is a criminal act in the USA.


This press release is not a prospectus for the purposes of Regulation (EU) 2017/1129 (the “Prospectus Regulation”) and has not been approved by any regulatory authority in any jurisdiction. In any EEA Member State, other than Sweden, this communication is only addressed to and is only directed at “qualified investors” in that Member State within the meaning of the Prospectus Regulation.


In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, “qualified investors” within the meaning of the Prospectus Regulation who are (i) persons having professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”); or (ii) “high net worth entities” falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “Relevant Persons”). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, Relevant Persons. Persons who are not Relevant Persons should not take any action on the basis of this announcement and should not act or rely on it.


This press release may contain certain forward-looking statements which reflect Annexin's current view of future events and financial and operational developments. Words such as "intends", "estimates", "expects", "may", "plans", "deems", "believes", "assesses", "anticipates", "will", and other similar expressions which imply indications or predictions regarding future developments or trends, and which are not based on historical facts, constitute forward-looking information. Forward-looking information is by nature affiliated with known and unknown risks and uncertainties since it is dependent on future events and circumstances. Forward-looking information does not constitute any guarantee regarding future results or development and the actual outcome may materially differ from forward-looking statements. The information, assessments and forward-looking statements in this press release are only relevant as of the date of this press release and may change without notice.